Invicta Diagnostic Ltd.
•₹ 69.50%
2026-08-21
PROS
- Company comfortably covers its interest (29.5x coverage)
- Company maintains a comfortable, low leverage position
- Company converts assets efficiently - asset turnover of 1.6x
CONS
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
EDIT COLUMNS| S.No. | Name | CMP Rs. | P/E | Mar Cap Rs.Cr. | Div Yld % | NP Qtr Rs.Cr. | Qtr Profit Var % | Sales Qtr Rs.Cr. | Qtr Sales Var % | ROCE % | OPM % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | APOLLOHOSP | 8799.00 | 60.55 | 126516.12 | 0.23 | 610.40 | 38.41 | 7043.50 | 20.56 | 21.73 | 15.70 |
| 2. | MANIPALHOS | 744.55 | 109.75 | 97936.41 | 0.00 | — | — | — | — | 13.93 | — |
| 3. | MAXHEALTH | 996.45 | 66.57 | 96982.14 | 0.20 | 322.96 | 4.87 | 2366.17 | 16.70 | 14.97 | 25.29 |
| 4. | ASTERDM | 800.70 | 219.01 | 69794.81 | 0.00 | 29.28 | -68.70 | 1310.68 | 21.60 | 11.46 | 19.53 |
| 5. | FORTIS | 910.80 | 65.62 | 68761.59 | 0.11 | 272.80 | 2.26 | 2545.03 | 17.46 | 14.07 | 21.28 |
| 6. | MEDANTA | 1419.05 | 68.60 | 38154.25 | 0.04 | 157.25 | -1.09 | 1304.05 | 26.50 | 20.50 | 21.99 |
| 7. | NH | 1782.70 | 44.64 | 36431.40 | 0.25 | 207.27 | 5.37 | 2683.63 | 78.05 | 16.20 | 17.43 |
| 8. | KIMS | 788.60 | 162.12 | 33121.71 | 0.00 | 37.40 | -56.00 | 1179.50 | 35.33 | 11.51 | 19.03 |
| 9. | LALPATHLAB | 1886.80 | 58.44 | 31669.72 | 1.09 | 1705.00 | 1172.39 | 7977.00 | 1090.95 | 29.56 | 31.03 |
| 10. | AGARWALEYE | 499.70 | 106.77 | 15841.80 | 0.00 | 55.02 | 44.56 | 614.02 | 25.97 | 14.32 | 27.75 |
| 11. | VIJAYA | 1489.70 | 81.84 | 15343.57 | 0.13 | 53.10 | 37.61 | 230.98 | 22.83 | 30.27 | 42.66 |
| 12. | INVICTA | 69.65 | 17.85 | 87.56 | 0.00 | — | — | — | — | 42.85 | — |
Detailed Comparison with:
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
No quarterly results found
We don't have this information yet. Please check back later.
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 16 | 30 | |
| 9 | 21 | |
| Operating Profit | 7 | 9 |
| OPM % | 45 | 31 |
| Other Income | 0 | 0 |
| Interest | 0 | 0 |
| Depreciation | 2 | 2 |
| 5 | 7 | |
| Tax % | 26 | 25 |
| Net Profit | 4 | 5 |
| EPS | 286 | 6 |
| Dividend Payout % | 0 | 0 |
| Minority Interest | -0 | -0 |
| Share of Associates | 0 | 0 |
| Adjusted EPS | 4 | 6 |
| Minority Interest | -0 | -0 |
| Share of Associates | 0 | 0 |
| Adjusted EPS | 4 | 6 |
Mar 2024
- 16
- 9
- Operating Profit
- 7
- OPM %
- 45
- Other Income
- 0
- Interest
- 0
- Depreciation
- 2
- 5
- Tax %
- 26
- Net Profit
- 4
- EPS
- 286
- Dividend Payout %
- 0
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 4
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 4
Mar 2025
- 30
- 21
- Operating Profit
- 9
- OPM %
- 31
- Other Income
- 0
- Interest
- 0
- Depreciation
- 2
- 7
- Tax %
- 25
- Net Profit
- 5
- EPS
- 6
- Dividend Payout %
- 0
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 6
- Minority Interest
- -0
- Share of Associates
- 0
- Adjusted EPS
- 6
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- Last Year:
- 40%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| LIABILITIES | - | - |
| Equity Capital | 0 | 8 |
| 10 | 6 | |
| Trade Payables | 1 | 0 |
| 5 | 6 | |
| Total Liabilities | 16 | 21 |
| ASSETS | - | - |
| 12 | 10 | |
| 0 | 4 | |
| 0 | 1 | |
| 1 | 1 | |
| Cash & Bank | 1 | 2 |
| 2 | 3 | |
| Total Assets | 16 | 21 |
| Total Debt | 4 | 4 |
| Net Working Capital | 1 | 4 |
| Contingent Liabilities | 0 | 0 |
| Book Value per Share | 740.17 | 17.37 |
| Face Value | 10.00 | 10.00 |
| Total Debt | 4 | 4 |
| Net Working Capital | 1 | 4 |
| Contingent Liabilities | 0 | 0 |
| Book Value per Share | 740.17 | 17.37 |
| Face Value | 10.00 | 10.00 |
Mar 2024
- Equity Capital
- 0
- 10
- Trade Payables
- 1
- 5
- Total Liabilities
- 16
- 12
- 0
- 0
- 1
- Cash & Bank
- 1
- 2
- Total Assets
- 16
- Total Debt
- 4
- Net Working Capital
- 1
- Contingent Liabilities
- 0
- Book Value per Share
- 740.17
- Face Value
- 10.00
- Total Debt
- 4
- Net Working Capital
- 1
- Contingent Liabilities
- 0
- Book Value per Share
- 740.17
- Face Value
- 10.00
Mar 2025
- Equity Capital
- 8
- 6
- Trade Payables
- 0
- 6
- Total Liabilities
- 21
- 10
- 4
- 1
- 1
- Cash & Bank
- 2
- 3
- Total Assets
- 21
- Total Debt
- 4
- Net Working Capital
- 4
- Contingent Liabilities
- 0
- Book Value per Share
- 17.37
- Face Value
- 10.00
- Total Debt
- 4
- Net Working Capital
- 4
- Contingent Liabilities
- 0
- Book Value per Share
- 17.37
- Face Value
- 10.00
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 6 | 7 | |
| Cash from Investing | -9 | -5 |
| Cash from Financing | 4 | -1 |
| 1 | 1 | |
| Free Cash Flow | 6 | 6 |
| OCF / Net Profit | 1.67 | 1.33 |
| Cumulative 5-Year FCF | 0 | 0 |
| OCF / Net Profit | 1.67 | 1.33 |
| Cumulative 5-Year FCF | 0 | 0 |
Mar 2024
- 6
- Cash from Investing
- -9
- Cash from Financing
- 4
- 1
- Free Cash Flow
- 6
- OCF / Net Profit
- 1.67
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.67
- Cumulative 5-Year FCF
- 0
Mar 2025
- 7
- Cash from Investing
- -5
- Cash from Financing
- -1
- 1
- Free Cash Flow
- 6
- OCF / Net Profit
- 1.33
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.33
- Cumulative 5-Year FCF
- 0
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| PER SHARE | - | - |
| EPS (₹) | 286.05 | 5.81 |
| Book Value (₹) | 740.17 | 17.37 |
| Dividend per Share (₹) | 0.00 | 0.00 |
| Cash EPS (₹) | 6.82 | 8.82 |
| PROFITABILITY | - | - |
| Operating Margin % | 44.77% | 30.57% |
| Net Margin % | 24.04% | 16.38% |
| ROE % | 39.10% | 40.48% |
| ROCE % | 38.55% | 42.85% |
| 23.95% | 26.57% | |
| EFFICIENCY | - | - |
| Debtor Days | 20 | 14 |
| Inventory Days | 9 | 5 |
| Payable Days | -1344 | -3136 |
| 1373 | 3155 | |
| FINANCIAL HEALTH | - | - |
| Debt to Equity (x) | 0.39x | 0.24x |
| Interest Coverage (x) | 51.80x | 29.51x |
| 1.62x | 2.37x | |
| GROWTH | - | - |
| Revenue Growth % | 0.00% | 90.11% |
| Operating Profit Growth % | 0.00% | 29.78% |
| Net Profit Growth % | 0.00% | 29.54% |
| 0.00% | -97.97% | |
| VALUATION | - | - |
| P/E (x) | 0.00x | 0.00x |
| P/B (x) | 0.00x | 0.00x |
| Dividend Yield % | 0.00% | 0.00% |
| 0.36x | 1.05x |
Mar 2024
- EPS (₹)
- 286.05
- Book Value (₹)
- 740.17
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 6.82
- Operating Margin %
- 44.77%
- Net Margin %
- 24.04%
- ROE %
- 39.10%
- ROCE %
- 38.55%
- 23.95%
- Debtor Days
- 20
- Inventory Days
- 9
- Payable Days
- -1344
- 1373
- Debt to Equity (x)
- 0.39x
- Interest Coverage (x)
- 51.80x
- 1.62x
- Revenue Growth %
- 0.00%
- Operating Profit Growth %
- 0.00%
- Net Profit Growth %
- 0.00%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.36x
Mar 2025
- EPS (₹)
- 5.81
- Book Value (₹)
- 17.37
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 8.82
- Operating Margin %
- 30.57%
- Net Margin %
- 16.38%
- ROE %
- 40.48%
- ROCE %
- 42.85%
- 26.57%
- Debtor Days
- 14
- Inventory Days
- 5
- Payable Days
- -3136
- 3155
- Debt to Equity (x)
- 0.24x
- Interest Coverage (x)
- 29.51x
- 2.37x
- Revenue Growth %
- 90.11%
- Operating Profit Growth %
- 29.78%
- Net Profit Growth %
- 29.54%
- -97.97%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 1.05x
Documents
Announcements
Nothing filed yet.
Annual Reports
Nothing filed yet.
Credit Ratings
Nothing filed yet.
Concalls
May 2026